Trials / Completed
CompletedNCT05056935
Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative Ileus
A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative Ileus in Subjects Undergoing Elective Bowel Resection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 131 (actual)
- Sponsor
- Newsoara Biopharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to establish preliminary evidence of the efficacy, safety, and tolerability of LB1148 for the treatment of return of gastrointestinal function and decrease Post-Operative Ileus in subjects undergoing elective bowel resection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LB1148 | A total of 700 mL of LB1148 will be administered orally as a split dose before surgery. |
| DRUG | Placebo | A total of 700 mL of placebo will be administered orally as a split dose before surgery. |
Timeline
- Start date
- 2019-07-09
- Primary completion
- 2020-07-22
- Completion
- 2020-08-08
- First posted
- 2021-09-27
- Last updated
- 2021-09-27
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05056935. Inclusion in this directory is not an endorsement.